<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03921775</url>
  </required_header>
  <id_info>
    <org_study_id>HR-RMZL-â…¢-GA</org_study_id>
    <nct_id>NCT03921775</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery</brief_title>
  <official_title>A Multicenter, Randomized, Single-blind, Parallel and Control Phase III Trial Evaluating the Efficacy and Safety of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of remimazolam tosilate
      compared to propofol for general anesthesia during elective surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage(%) of paticipants who experienced successful anesthesia during operation in each group</measure>
    <time_frame>Average of 2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from start of investigational medicinal product administration to loss of consciousness</measure>
    <time_frame>Average of 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from stop of investigational medicinal product to MOAA/S Score=5</measure>
    <time_frame>Average of 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from stop of investigational medicinal product to Aldrete Score&gt;9</measure>
    <time_frame>Average of 2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Anesthesia for Elective Surgery Patients</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV pumping of remimazolam tosilate at 6mg/kg/h for anesthesia induction and 1mg/kg/h for anesthesia maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV pumping of propofol at 120~150mg/kg/h for anesthesia induction and 3~12mg/kg/h for anesthesia maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam Tosilate</intervention_name>
    <description>For induction and maintenance of general anesthesia</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>For induction and maintenance of general anesthesia</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclution Criteria:

          1. 18~60 years, female or male

          2. Patients scheduled for an elective surgical procedure(mechanical ventilation via
             endotracheal tube)

          3. BMI: 18~30 kg/m2

          4. Patients understand clearly and participate in the study voluntarily, and sign the
             informed consent

        Exclusion criteria:

          1. Patients scheduled for emergency surgery

          2. Patients with a history of drug abuse and / or alcohol abuse 2 years prior to the
             screening period

          3. One or more of the laboratory findings fall out of the limitations for this
             study(platelet,hemoglobin,aspartate aminotransferase,etc.)

          4. Pregnant women or those in lactation period

          5. Allergic to drugs used in the study

          6. Patients with respiratory management difficulties (Modified Mallampati grade IV)

          7. Patients have participated in other clinical trial within the 3 months prior to
             randomization

          8. Any patient judged by the Principal Investigator (PI) or Sub-Investigator to be
             inappropriate for the subject for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

